Patents Issued in July 3, 2018
  • Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
    Patent number: 10011605
    Abstract: The present invention relates to a process for preparation of triazolo[4,5-d] pyrimidine cyclopentane compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention also provides novel compounds that can be used as intermediates in the process for preparing triazolo[4,5-d] pyrimidine cyclopentane compounds. The process and the intermediates are particularly useful for the preparation of ticagrelor and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: July 3, 2018
    Assignee: FLAMMA SPA
    Inventors: Anna Rencurosi, Massimo Previtali, Federico Della Negra, Francesco Mormile, Renato Canevotti
  • Imidazopyrazinones as PDE1 inhibitors
    Patent number: 10011606
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: July 3, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing
  • Ethynyl derivatives
    Patent number: 10011607
    Abstract: The present invention relates to compounds of formula I wherein R1 is hydrogen, F or Cl; L is a bond or lower alkylene; R2 is —(CH2)nO-lower alkyl, lower alkyl substituted by halogen, —(CH2)nC(O)O-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, ?O, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by —(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or —(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: July 3, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Georg Jaeschke, Fionn O'Hara, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof
    Patent number: 10011608
    Abstract: Provided are a compound of Formula 1 and an organic electric element including a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode and comprising the compound, the element showing decreased driving voltage, improved luminescent efficiency, stability, and life span.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: July 3, 2018
    Assignee: DUK SAN NEOLUX CO., LTD.
    Inventors: Wonsam Kim, Yuri Kim, Seunghoon Hahn, HyunJu Song, Junghwan Park, Sunhee Lee, Jungwook Lee
  • Heterocyclic compounds
    Patent number: 10011609
    Abstract: The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: July 3, 2018
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Ranjit C. Desai, Brijeshkumar Srivastava
  • Selective BACE1 inhibitors
    Patent number: 10011610
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Michael Remick, Simon James Richards, Adam Jan Sanderson
  • Histone deacetylase inhibitors and methods for use thereof
    Patent number: 10011611
    Abstract: The present invention relates to methods of modulating (for example inhibiting) activity of histone deacetylases (HDACs) and/or treating HDACs-associated diseases including, for example, cancers, inflammatory disorders, neurodegenerative disorders, etc. The invention also provides novel compounds and compositions thereof, methods of preparation of the same, as well as methods of use of the same for inhibition of HDACs and/or treatment of HDAC-associated diseases.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: July 3, 2018
    Assignee: REACTION BIOLOGY CORP.
    Inventors: Haiching Ma, Yuren Wang
  • Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
    Patent number: 10011612
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: July 3, 2018
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • Polycyclic pyridone derivative having integrase inhibitory activity
    Patent number: 10011613
    Abstract: The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: July 3, 2018
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tomokazu Yoshinaga, Kouhei Nodu
  • Bis-?-carboline compound and preparation method, pharmaceutical composition and use thereof
    Patent number: 10011614
    Abstract: Disclosed in the present invention are a bis-?-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-?-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-?-carboline compound is prepared through the condensation of ?-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-?-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-?-carboline compound in preparing drugs resistant to tumors such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: July 3, 2018
    Assignee: Xinjiang Huashidan Pharmaceutical Research Co., Ltd
    Inventors: Zihou Wang, Jialin Wu, Jing Shang, Qin Ma, Buxi Shi, Liang Guo, Wenxi Fan, Jie Sun
  • Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties
    Patent number: 10011615
    Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
  • Boron-containing small molecules as antiprotozoal1 agents
    Patent number: 10011616
    Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 3, 2018
    Assignee: MMV MEDICINES FOR MALARIA VENTURE
    Inventors: Yong-Kang Zhang, Jacob J. Plattner, Robert T. Jacobs
  • Isocyanate derived organosilanes
    Patent number: 10011617
    Abstract: The invention relates to isocyanate derived organosilanes and the use thereof. The isocyanate derived organosilanes can be reacted with inorganic substrates, such as oxide particles, to result in a surface modified inorganic substrate.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: July 3, 2018
    Assignee: THE CHEMOURS COMPANY FC, LLC
    Inventors: John Christopher Sworen, Gerald Oronde Brown, Tatsiana Haidzinskaya, Ewa Kohler
  • Process for reducing the chlorine content of organotetraphosphites
    Patent number: 10011619
    Abstract: Universally usable process for reducing the chlorine content of organotetraphosphites.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: July 3, 2018
    Assignee: EVONIK DEGUSSA GMBH
    Inventors: Katrin Marie Dyballa, Robert Franke
  • Lipophenol compounds and uses thereof
    Patent number: 10011620
    Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: July 3, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE D'AUVERGNE, UNIVERSITE DE MONTPELLIER
    Inventors: Philippe Brabet, David Cia, Laurent Guillou, Christian Hamel, Claire Vigor, Thierry Durand, Céline Crauste, Joseph Vercauteren
  • Method for producing silica gel-immobolized phosphonium salt catalysts
    Patent number: 10011621
    Abstract: Disclosed herein is a method for producing silica gel-immobilized phosphonium salt catalysts including the steps of (a) reacting a silane compound with a silica gel in the presence of xylene, to obtain a catalyst precursor having a haloalkyl group or a haloaryl group, wherein the silane compound has a haloalkyl group or a haloaryl group, and a proportion of the silane compound is from 0.001 to 0.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: July 3, 2018
    Assignees: MARUZEN PETROCHEMICAL CO., LTD., National Institute of Advanced Industrial Science and Technology
    Inventors: Masuo Yamazaki, Takashi Naniki, Toshikazu Takahashi, Hiroyuki Yasuda, Shouji Yamamoto
  • Compounds, compositions, and methods for the treatment of cancers
    Patent number: 10011622
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 3, 2018
    Assignee: PLACON THERAPEUTICS, INC.
    Inventors: Mark T. Bilodeau, Benoît Moreau, Adam H. Brockman
  • Alkoxide compound, thin film-forming starting material, and thin film formation method
    Patent number: 10011623
    Abstract: The alkoxide compound of the present invention is characteristically represented by the following general formula (I):
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 3, 2018
    Assignee: ADEKA CORPORATION
    Inventors: Atsushi Sakurai, Masako Hatase, Tomoharu Yoshino, Masaki Enzu
  • Transition metal compound having heteroatom, catalyst composition including the same and preparation method of polymer using the catalyst composition
    Patent number: 10011624
    Abstract: The present invention discloses a transition metal compound including a heteroatom and having a novel structure, a catalyst composition including the same, and a preparation method of a polymer using the catalyst composition. The transition metal compound according to an embodiment of the present invention may be used as a catalyst having good copolymerization properties, and a polymer having a high molecular weight at a low density region may be prepared.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: July 3, 2018
    Assignee: LG CHEM, LTD.
    Inventors: Young Shil Do, Jin Sam Gong, Yun Jin Lee, Choong Hoon Lee, Seung Hwan Jung
  • Processing facility
    Patent number: 10011625
    Abstract: Biomass feedstocks (e.g., plant biomass, animal biomass, and municipal waste biomass) are processed to produce useful products, such as fuels. For example, systems are described that can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy materials, to produce a product or intermediate, e.g., energy, a food, a fuel, or a material.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: July 3, 2018
    Assignee: XYLECO, INC.
    Inventors: Marshall Medoff, Thomas Craig Masterman
  • Method for the purification of decitabine
    Patent number: 10011626
    Abstract: A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension. The forming step may further comprise after adding ethanol to provide a mixture of dimethylacetamide and ethanol: cooling the mixture; isolating the solid decitabine present in the cooled mixture; and evaporating residual dimethylacetamide and ethanol from the solid decitabine to provide the purified decitabine. The mixture of dimethylacetamide and ethanol may be heated. The purification method preferably results in decitabine having a ratio of the ?-anomer of decitabine to the ?-anomer of decitabine of at least about 99.9:0.1.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: July 3, 2018
    Assignee: Johnson Matthey Public Limited Company
    Inventor: Daniel James Coughlin
  • C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof
    Patent number: 10011627
    Abstract: C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of the compounds, preparation methods thereof, pharmaceutical compositions containing the compounds, and applications thereof are described. Compounds of formula (I) are useful as therapeutic agents, and particularly as sodium-dependent glucose contransporter protein (SGLT) inhibitors.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: July 3, 2018
    Assignee: YOUNGENE THERAPEUTICS CO., LTD
    Inventors: Huijuan Zhong, Jianchun Liao, Hongping Yu, Yaochang Xu, Qing Li, Jianghua Chen, Peng Gao, Songliang Tan, Shaobao Wang
  • Multivalent sialic acid derivatives
    Patent number: 10011628
    Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: July 3, 2018
    Assignee: ADENOVIR PHARMA AB
    Inventors: Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
  • Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
    Patent number: 10011629
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: July 3, 2018
    Assignees: Cocrystal Pharma, Inc., Emory University
    Inventors: Steven J. Coats, Franck Amblard, Seema Mengshetti, Hao Li, Raymond F. Schinazi
  • Cyclic dinucleotides for cytokine induction
    Patent number: 10011630
    Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 3, 2018
    Assignee: INVIVOGEN
    Inventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
  • Stapled helical peptides and methods of synthesis
    Patent number: 10011631
    Abstract: The present disclosure relates to the design and generation of stapled helical peptides that perturb protein-protein interactions (PPIs). The methods disclosed herein for preparing stapled peptides involve providing a peptide having a first amino acid that is functionalized with a salicylaldehyde ester side group and a second amino acid functionalized with a 1,2-hydroxyl amine side group; reacting the first and second amino acids to generate an N,O-benzylidene acetal moiety; and performing acidolysis of the resultant N,O-benzylidene acetal moiety to generate the stapled peptide. In many forms, the stapled helical peptides described herein are not hydrophobic.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: July 3, 2018
    Assignee: The University of Hong Kong
    Inventors: Xuechen Li, Chi-Lung Lee, Jiaochao Xu
  • PSMA imaging agents
    Patent number: 10011632
    Abstract: Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: July 3, 2018
    Assignee: Siemens Medical Solutions USA, Inc.
    Inventors: Eric Wang, Hartmuth C. Kolb, Anna Katrin Szardenings, Changhui Liu, Joseph C. Walsh, Gang Chen, Anjana Sinha, Dhanalakshmi Kasi, Chul Yu, Umesh B. Gangadharmath, Wei Zhang, Tieming Zhao, Vani P. Mocharla
  • IBAT inhibitors for the treatment of liver diseases
    Patent number: 10011633
    Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: July 3, 2018
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Hans Graffner, Ingemar Starke
  • Inhibitors of beta integrin-G protein alpha subunit binding interactions
    Patent number: 10011634
    Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: July 3, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventor: Xiaoping Du
  • Cyclic peptide conjugates and methods of use
    Patent number: 10011635
    Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: July 3, 2018
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, MODULATION THERAPEUTICS, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
  • Inhibitors of metastasis
    Patent number: 10011636
    Abstract: The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: July 3, 2018
    Assignees: BIOMARCK PHARMACEUTICALS LTD, NORTH CAROLINA STATE UNIVERSITY
    Inventors: Indu Parikh, Kenneth B. Adler
  • Ultra-pure agonists of guanylate cyclase C, method of making and using same
    Patent number: 10011637
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 3, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • PTEN antagonist peptides and methods of using the same
    Patent number: 10011638
    Abstract: The presently disclosed subject matter relates to antagonists of PTEN and methods of using the same. In particular, the presently disclosed subject matter provides for PTEN antagonist peptides for use in treating central nervous system disorders. In an exemplary embodiment, the presently disclosed subject matter provides methods for promoting nerve fiber growth in a subject by administering to the subject a therapeutically effective amount of a PTEN antagonist peptide.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: July 3, 2018
    Assignee: Shriners Hospitals for Children
    Inventor: Shuxin Li
  • Peptidomimetic compounds
    Patent number: 10011639
    Abstract: The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: July 3, 2018
    Assignee: NOLIVA THERAPEUTICS LLC
    Inventors: Renato T. Skerlj, Andrew C. Good
  • Capsid-modified rAAV vector compositions and methods therefor
    Patent number: 10011640
    Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 3, 2018
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
  • ABD binding polypeptide
    Patent number: 10011641
    Abstract: The disclosure provides an ABD binding polypeptide comprising an ABD binding motif BM, which motif consists of an amino acid sequence selected from EX2X3X4AX6X7EIX10X11LPNLX16X17X18QX20X21AFIX25X26LX28D (SEQ ID NO: 166) and amino acid sequences with at least 89 % identity thereto.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: July 3, 2018
    Assignee: AFFIBODY AB
    Inventors: Per Jonasson, Pär Eklund
  • Methods of treating of diabetes and obesity using FGF21 mutants
    Patent number: 10011642
    Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 3, 2018
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Freeze-dried preparation containing high-purity PTH and method for producing same
    Patent number: 10011643
    Abstract: [Problem] Provided is a freeze-dried preparation containing high-purity PTH peptide and a method for the production thereof. Also provided is a test method for PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like. [Solution] In the present invention, the presence of PTH analogs produced during the manufacturing process of a freeze-dried preparation containing PTH peptide was confirmed. The production of these PTH analogs was also discovered to be markedly prevented or reduced by controlling exposure of the solution containing PTH peptide and the like to air environments within a pharmaceutical production facility.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: July 3, 2018
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Fumihide Nishio, Takuji Maejima, Yoshiro Mitome
  • Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof
    Patent number: 10011644
    Abstract: Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: July 3, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Petra Rueger, Tilman Schlothauer, Stefan Seeber
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10011645
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: July 3, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Recombinant decoy receptor 3 for treating spinal cord injury
    Patent number: 10011646
    Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: July 3, 2018
    Inventors: Shie-Liang Hsieh, Henrich Cheng, Wen-Hung Huang, Chuan-Wen Chiu, Shao-Ji Lin
  • IL-33 antagonists and uses thereof
    Patent number: 10011647
    Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 3, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
  • Human monoclonal antibody against the VP1 protein of JC virus
    Patent number: 10011648
    Abstract: A human neutralizing monoclonal antibody is directed against the VP1 protein of JC virus. The JC virus is responsible for progressive multifocal leukoencephalopathy (PML). The antibody is used in a therapeutic or prophylactic treatment of a JCV infection or of a disease associated with a JCV infection, such as progressive multifocal leukoencephalopathy (PML). The antibody is also used in the diagnosis of JCV infections or of diseases associated with JCV infections.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: July 3, 2018
    Assignee: POMONA RICERCA S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • High affinity synbodies for influenza
    Patent number: 10011649
    Abstract: Composition of synbodies that bind influenza. The synbodies are composed of two peptides joined on a scaffold.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: July 3, 2018
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Christopher Diehnelt, Nidhi Gupta, Valeriy Domenyuk, Zhan-Gong Zhao, Stephen Johnston
  • Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
    Patent number: 10011650
    Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: July 3, 2018
    Assignee: Corixa Corporation
    Inventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
  • Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
    Patent number: 10011651
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: July 3, 2018
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Immunoglobulin-like molecules directed against fibronectin-EDA
    Patent number: 10011652
    Abstract: The present invention is concerned with immunoglobulin (Ig)-like molecules or fragments thereof for use in treatment, prevention, or prevention of progression of adverse cardiac remodelling and conditions resulting from or relating to myocardial infarction and pressure-overload, such as heart failure, aneurysm formation and remote myocardial fibrosis and for use in improving angiogenesis, preferably after ischemic injury. The invention also provides nucleic acid molecules encoding said Ig-like molecules, vectors comprising same, and host cells comprising same.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: July 3, 2018
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventor: Faith Arslan
  • Antibodies to tau and methods of treatment therewith
    Patent number: 10011653
    Abstract: Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: Mansuo Lu Hayashi, Jirong Lu, David Driver, Alberto Alvarado
  • Antibodies directed to IL-17A/IL-17F heterodimers
    Patent number: 10011654
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: July 3, 2018
    Assignee: Genentech, Inc.
    Inventors: David P. Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
  • Compositions and methods for the identification and isolation of cell-membrane protein specific binding moieties
    Patent number: 10011655
    Abstract: Disclosed are methods of identifying binding moieties that recognize antigens displayed on cells, such as membrane proteins or recombinant proteins that display eptiopes on the surface of cells. Binding moieties capable of binding membrane proteins can be difficult to obtain because these proteins can depend on their native environments for structural integrity. In some methods scFv phage display libraries are panned against whole cells expressing a membrane protein in an emulsion. Certain methods further permit discrimination of binding moieties according to their affinity or avidity for a target. This approach allows rapid identification of cell surface epitope specific antibodies for research, diagnostics, and immunotherapeutics.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: July 3, 2018
    Assignee: AxioMx, Inc.
    Inventors: Michael Weiner, Margaret Kiss